FMFelix Machleidt

Felix Machleidt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Felix Machleidt has a total of 178 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander F. Krapalis

    Department of Internal Medicine I, University Hospital of Schleswig-Holstein, Luebeck, Germany

    3 shared publications
  • Florian Kurth

    Department of Infectious Diseases and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

    3 shared publications
  • Friedhelm Sayk

    Department of Internal Medicine I (K.A.I., F.S., T.W., F.M., H.L.), Section of Experimental and Clinical Endocrinology, University of Lübeck, 23538 Lübeck, Germany

    3 shared publications
  • Hendrik Lehnert

    Department of Internal Medicine I (K.A.I., F.S., T.W., F.M., H.L.), Section of Experimental and Clinical Endocrinology, University of Lübeck, 23538 Lübeck, Germany

    3 shared publications
  • Holger Müller-Redetzky

    Affiliation Charité–Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany

    3 shared publications
  • Leif Erik Sander

    Department of Infectious Diseases, Respiratory, and Critical Care Medicine, Charite University Medical Center Berlin, Berlin, Germany

    3 shared publications

Latest Publications

  • Intranasal orexin A modulates sympathetic vascular tone: a pilot study in healthy male humans

    by Moritz Meusel, Jacqueline Voß, Alexander Krapalis, Felix Machleidt, Reinhard Vonthein, Manfred Hallschmid, Friedhelm Sayk

    Our pilot study adds another important part to the complex network of neuroendocrine-sympathetic interaction. Our results demonstrate that intranasal orexin A elicits an excitatory effect on sympathetic vascular tone superordinate to mere baroreflex feedback regulation. This resetting of the baroreflex set point suggests an activation of hypothalamic core centers such as the paraventricular nucleus (PVN). The role of the orexinergic system in the development of neurogenic arterial hypertension warrants further investigations.


  • Open Access

    A proteomic survival predictor for COVID-19 patients in intensive care

    by Vadim Demichev, Pinkus Tober-Lau, Tatiana Nazarenko, Oliver Lemke, Simran Kaur Aulakh, Harry J. Whitwell, Annika Röhl, Anja Freiwald, Mirja Mittermaier, Lukasz Szyrwiel, et al.

    Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to optimize allocation of treatment and resources in intensive care, as clinically established risk assessments such as SOFA and APACHE II scores show only limited performance for predicting the survival of severely ill COVID-19 patients. Additional tools are also needed to monitor treatment, including experimental therapies in clinical trials. Comprehensively capturing human physiology, we speculated that proteomics in combination with new data-driven analysis strategies could produce a new generation of prognostic discriminators. We studied two independent cohorts of patients with severe COVID-19 who required intensive care and invasive mechanical ventilation. SOFA score, Charlson comorbidity index, and APACHE II score showed limited performance in predicting the COVID-19 outcome. Instead, the quantification of 321 plasma protein groups at 349 timepoints in 50 critically ill patients receiving invasive mechanical ventilation revealed 14 proteins that showed trajectories different between survivors and non-survivors. A predictor trained on proteomic measurements obtained at the first time point at maximum treatment level (i.e. WHO grade 7), which was weeks before the outcome, achieved accurate classification of survivors (AUROC 0.81). We tested the established predictor on an independent validation cohort (AUROC 1.0). The majority of proteins with high relevance in the prediction model belong to the coagulation system and complement cascade. Our study demonstrates that plasma proteomics can give rise to prognostic predictors substantially outperforming current prognostic markers in intensive care.


  • Top Cited Papers
    Open Access

    COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis

    by Robert Lorenz Chua, Soeren Lukassen, Saskia Trump, Bianca P. Hennig, Daniel Wendisch, Fabian Pott, Olivia Debnath, Loreen Thürmann, Florian Kurth, Maria Theresa Völker, et al.

    To investigate the immune response and mechanisms associated with severe coronavirus disease 2019 (COVID-19), we performed single-cell RNA sequencing on nasopharyngeal and bronchial samples from 19 clinically well-characterized patients with moderate or critical disease and from five healthy controls. We identified airway epithelial cell types and states vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In patients with COVID-19, epithelial cells showed an average three-fold increase in expression of the SARS-CoV-2 entry receptor ACE2, which correlated with interferon signals by immune cells. Compared to moderate cases, critical cases exhibited stronger interactions between epithelial and immune cells, as indicated by ligand–receptor expression profiles, and activated immune cells, including inflammatory macrophages expressing CCL2, CCL3, CCL20, CXCL1, CXCL3, CXCL10, IL8, IL1B and TNF. The transcriptional differences in critical cases compared to moderate cases likely contribute to clinical observations of heightened inflammatory tissue damage, lung injury and respiratory failure. Our data suggest that pharmacologic inhibition of the CCR1 and/or CCR5 pathways might suppress immune hyperactivation in critical COVID-19.


  • Open Access

    Suppressive myeloid cells are a hallmark of severe COVID-19

    by Jonas Schulte-Schrepping, Nico Reusch, Daniela Paclik, Kevin Baßler, Stephan Schlickeiser, Bowen Zhang, Benjamin Krämer, Tobias Krammer, Sophia Brumhard, Lorenzo Bonaguro, et al.

    ‘Severe Acute Respiratory Syndrome - Coronavirus-2’ (SARS-CoV-2) infection causes Coronavirus Disease 2019 (COVID-19), a mild to moderate respiratory tract infection in the majority of patients. A subset of patients, however, progresses to severe disease and respiratory failure with acute respiratory distress syndrome (ARDS). Severe COVID-19 has been associated with increased neutrophil counts and dysregulated immune responses. The mechanisms of protective immunity in mild forms and the pathogenesis of dysregulated inflammation in severe courses of COVID-19 remain largely unclear. Here, we combined two single-cell RNA-sequencing technologies and single-cell proteomics in whole blood and peripheral blood mononuclear cells (PBMC) to determine changes in immune cell composition and activation in two independent dual-center patient cohorts (n=46+n=54 COVID-19 samples), each with mild and severe cases of COVID-19. We observed a specific increase of HLA-DR hi CD11c hi inflammatory monocytes that displayed a strong interferon (IFN)-stimulated gene signature in patients with mild COVID-19, which was absent in severe disease. Instead, we found evidence of emergency myelopoiesis, marked by the occurrence of immunosuppressive pre-neutrophils and immature neutrophils and populations of dysfunctional and suppressive mature neutrophils, as well as suppressive HLA-DR to monocytes in severe COVID-19. Our study provides detailed insights into systemic immune response to SARS-CoV-2 infection and it reveals profound alterations in the peripheral myeloid cell compartment associated with severe courses of COVID-19.


  • GHRH-mediated GH release is associated with sympathoactivation and baroreflex resetting: a microneurographic study in healthy humans

    by Moritz Meusel, Magdalena Herrmann, Felix Machleidt, Klaas Frederik Franzen, Alexander F. Krapalis, Friedhelm Sayk

    Background: Previous research suggested substantial interactions of growth hormone (GH) and sympathetic nervous activity. This cross-talk can be presumed both during physiological (e.g. slow-wave sleep) as well as pathological conditions of GH-release. However, microneurographic studies of muscle sympathetic nerve activity (MSNA) and assessment of baroreflex function during acute GH-releasing hormone (GHRH) mediated GH-release were not conducted so far. Methods: In a balanced, double blind cross-over design GHRH or placebo (normal saline), were intravenously (iv) administered to 11 healthy male volunteers. MSNA was assessed microneurographically and correlated with blood pressure (BP) and heart rate (HR) at rest before (pre-), as well as 30-45 (post-I) and 105-120 minutes (post-II) after respective injections. Additionally, baroreflex function was assessed via graded infusion of vasoactive drugs. Results: GHRH increased GH serum levels as intended. Resting MSNA showed significant net increases of both burst rate and total activity from pre- to post-I and post-II following GHRH injections compared to placebo (ANOVA for treatment and time, burst rate: p=0.028; total activity: p=0.045), while BP and HR were not altered. ANCOVA revealed that the dependent variable MSNA was not affected by the independent variables mean arterial BP (MAP) or HR (MAP: p=0.006; HR: p=0.003). Baroreflex sensitivity at baroreflex challenge was not altered. Conclusion: GHRH mediated GH-release is associated with a significant sympathoactivation at central nervous sites superordinate to the simple baroreflex feedback loop, since GH induced a baroreflex-resetting without altering baroreflex sensitivity.


  • Intranasally administered Orexin-A does not activate sympathetic baroreflex function in healthy humans

    by F Sayk, J Reiter, A Krapalis, F Machleidt, M Meusel, M Hallschmid, H Lehnert

    Background: Orexin-A is a hypothalamic hormone crucially involved in the regulation of sleep/wake states. Orexin-A was previously reported to induce blood pressure (BP) relevant sympathetic activation in animals and orexin-neurons were shown to project towards BP regulating brain structures. In humans intranasal (i.n.) administration has been shown to effectively deliver neuropeptides directly to the central nervous system. In human narcolepsy, a disorder characterized by deficient orexin-A signalling, i.n. orexin-A provided functional effects of sleep architecture. However, sympathetic blood pressure effects remain to be elucidated. Using highly specific microneurographic techniques we investigated, whether i.n. orexin-A would alter sympathetic baroreflex function in healthy humans. Methods: In a double-blinded cross-over design orexin-A (500 nmol) or placebo (sterile water) was administered i.n. in 12 wake normotensive males. Muscle sympathetic nerve activity (MSNA) was assessed microneurographically and correlated with oscillometric BP and heart rate at supine rest and during pharmacologic baroreceptor challenge before (pre-substance period) and from 30 – 60 minutes after the orexin-A challenge (post-substance period). Results: Orexin-A did not produce any changes of BP or heart rate comparing pre- vs. post-substance periods as well as orexin-A vs. placebo condition. Moreover, resting MSNA was not increased and sympathetic baroreflex sensitivity was not altered during baroreceptor testing with vasoactive drugs at the respective periods. Conclusion: In this pilot study we found that i.n. orexin-A at doses previously shown to induce distinct central nervous effects in humans did not alter sympathetic baroreflex function in healthy subjects.

  • Open Access

    Intranasal Insulin Suppresses Systemic but Not Subcutaneous Lipolysis in Healthy Humans

    by K. Alexander Iwen, Thomas Scherer, Martin Heni, Friedhelm Sayk, Toni Wellnitz, Felix Machleidt, Hubert Preissl, Hans-Ulrich Häring, Andreas Fritsche, Hendrik Lehnert, et al.

    Context: Insulin infused into the central nervous system of rats suppresses lipolysis in white adipose tissue, indicating a role of brain insulin in regulating systemic lipid metabolism. Objective: We investigated whether central nervous insulin delivery suppresses lipolysis in healthy humans. Design: Placebo-controlled, balanced within-subject comparisons were performed in both a main and an independent corroborative experiment. Setting/Participants/Intervention: Two groups of healthy volunteers were examined at the German University Clinics of Lübeck and Tübingen, respectively, with molecular analyses taking place at Mt Sinai School of Medicine (New York, New York). The 14 healthy male subjects of the main study and the 22 women and 5 men of the corroborative study each received 160 IU of human insulin intranasally. Main Outcome Measures: In the main study, we measured systemic levels of free fatty acids (FFAs), triglycerides, and glycerol and the rate of appearance of deuterated glycerol as an estimate of lipolysis before and after intranasal insulin administration. We also analyzed the expression of key lipolytic enzymes in sc fat biopsies and measured blood glucose and glucoregulatory hormones. In the corroborative study, FFA concentrations were assessed before and after intranasal insulin administration. Results: In the main experiment, intranasal insulin suppressed circulating FFA concentrations and lipolysis (rate of appearance of deuterated glycerol) in the absence of significant changes in circulating insulin levels. Lipolytic protein expression in sc adipose tissue was not affected. The corroborative study confirmed that intranasal insulin lowers systemic FFA concentrations. Conclusions: Our findings indicate that brain insulin controls systemic lipolysis in healthy humans by predominantly acting on non-sc adipose tissue.


  • Open Access

    Experimental Hyperleptinemia Acutely Increases Vasoconstrictory Sympathetic Nerve Activity in Healthy Humans

    by Felix Machleidt, Paul Simon, Alexander F. Krapalis, Manfred Hallschmid, Hendrik Lehnert, Friedhelm Sayk

    Background: Obesity and arterial hypertension are tightly connected. Obese individuals show significant elevation of vasoconstrictory muscle sympathetic nerve activity (MSNA). Obesity-related hyperleptinemia might play a key role in mediating these effects. Leptin is synthesized in proportion to body fat mass and activates SNA in animal models. In humans, however, direct evidence linking hyperleptinemia to sympathetic activation has not yet been established. In the present study, we characterize the effects of acute hyperleptinemia on microneurographically recorded SNA in humans. Methods: In a balanced, double-blind crossover design, 12 healthy normal-weight males received an iv bolus of leptin or placebo. MSNA (bursts per minute) was continuously recorded using a microneurographic technique. Ten-minute periods were analyzed at resting periods before (t−100) and at 20 (t20), 60 (t60), and 140 (t140) minutes after substance administration. Blood pressure and heart rate (HR) were recorded simultaneously. Results: Baseline values of MSNA, blood pressure, and HR were comparable in both conditions (MSNA: t−100, 24.3 ± 1.6 vs 22.7 ± 1.7, not significant). After application of leptin, MSNA showed a significant increase (t20, 31.0 ± 1.9 vs. 24.9 ± 1.8, P = .05) that persisted until the end of the experiment (t60, P = .008; t140, P = .004). There were no significant changes in blood pressure and HR. Conclusions: Acute experimental hyperleptinemia has significant central nervous excitatory effects on vasoconstrictory sympathetic outflow as measured by MSNA in healthy men. These results suggest that leptin acts as an important mediator linking obesity to elevated MSNA and potentially to the development of hypertension.


  • Ghrelin modulates baroreflex-regulation of sympathetic vasomotor tone in healthy humans

    by Alexander F. Krapalis, Jacqueline Reiter, Felix Machleidt, K. Alexander Iwen, Christoph Dodt, Hendrik Lehnert, Friedhelm Sayk

    Ghrelin, a neuropeptide originally known for its growth hormone-releasing and orexigenic properties, exerts important pleiotropic effects on the cardiovascular system. Growing evidence suggests that these effects are mediated by the sympathetic nervous system. The present study aimed at elucidating the acute effect of ghrelin on sympathetic outflow to the muscle vascular bed (muscle sympathetic nerve activity, MSNA) and on baroreflex-mediated arterial blood pressure (BP) regulation in healthy humans. In a randomized double-blind cross-over design, 12 lean young men were treated with a single dose of either ghrelin 2 μg/kg iv or placebo (isotonic saline). MSNA, heart rate (HR), and BP were recorded continuously from 30 min before until 90 min after substance administration. Sensitivity of arterial baroreflex was repeatedly tested by injection of vasoactive substances based on the modified Oxford protocol. Early, i.e., during the initial 30 min after ghrelin injection, BP significantly decreased together with a transient increase of MSNA and HR. In the course of the experiment (>30 min), BP approached placebo level, while MSNA and HR were significantly lower compared with placebo. The sensitivity of vascular arterial baroreflex significantly increased at 30–60 min after intravenous ghrelin compared with placebo, while HR response to vasoactive drugs was unaltered. Our findings suggest two distinct phases of ghrelin action: In the immediate phase, BP is decreased presumably due to its vasodilating effects, which trigger baroreflex-mediated counter-regulation with increases of HR and MSNA. In the delayed phase, central nervous sympathetic activity is suppressed, accompanied by an increase of baroreflex sensitivity.


  • Die Rolle des Gehirns in der Regulation des Stoffwechsels

    by F Machleidt, H Lehnert

    Das Gehirn wird fortlaufend mit Informationen über die Verteilung und Menge der Energiereserven aus der Körperperipherie versorgt. Endokrine, autonome und kognitiv-hedonische Signale werden zentral integriert und rufen über anabole und katabole Signalwege Effekte auf den Gesamtorganismus hervor. Die Hormone Insulin und Leptin sind bedeutende Adipositassignale, d. h. ihre Konzentrationen im Blut spiegeln die Menge an Körperfett wieder und bilden einen negativen Feedbackmechanismus zwischen Körperperipherie und dem zentralen Nervensystem. Der hypothalamische Nucleus arcuatus ist die wichtigste zentralnervöse Struktur, die diese Informationen verarbeitet. Weiterhin ist das ZNS in der Lage, direkt die Konzentrationsänderungen bestimmter Nährstoffe zu messen und auf diese zu reagieren. Für die Entwicklung effektiver Therapien von Störungen der Energiebalance ist die weitere Aufklärung dieser neurobiologischen Vorgänge von entscheidender Bedeutung. Diese Arbeit gibt einen Überblick über die zentralnervöse Stoffwechselregulation und die ihr zugrunde liegenden molekularen Mechanismen. The brain is continuously supplied with information about the distribution and amount of energy stores from the body periphery. Endocrine, autonomic and cognitive-hedonic signals are centrally integrated and exert effects on the whole organism via anabolic and catabolic pathways. The adiposity signals insulin and leptin reflect the amount of body fat and are part of a negative feedback mechanism between the periphery and the central nervous system. The hypothalamic arcuate nucleus is the most important central nervous structure, which integrates this information. Furthermore, the CNS is able to directly measure and to respond to changes in the concentration of certain nutrients. In order to develop effective therapies for the treatment of disorders of energy balance the further elucidation of these neuro-biological processes is of crucial importance. This article provides an overview of the CNS regulation of metabolism and its underlying molecular mechanisms.